Central Stimulants in a Stressed Brain: Evidence Synthesis of Benefits, Burnout Risk, and Clinical Safeguards in ADHD

Central stimulants improve core ADHD symptoms, yet day-to-day benefit and tolerability vary under sustained psychosocial or financial stress. We reviewed clinical outcomes relevant to stress-linked vulnerability and integrated mechanistic evidence on stress-sensitive prefrontal-nucleus accumbens dopamine-glutamate pathways.

Narrative evidence synthesis with systematic searches of MEDLINE/PubMed, Embase and PsycINFO (2010-March 2025). Dual screening and data extraction; risk of bias (RoB 2/ROBINS-I) and GRADE certainty by outcome domain. Meta-analysis was prespecified but not executed because no domain met pooling criteria; findings are presented narratively by outcome domain and stress context.

Fifteen primary studies met inclusion (8 RCTs; 7 cohorts). Stimulants consistently improved inattention/working memory and daytime task efficiency. Evidence for emotion- and stress-linked outcomes (emotion dysregulation, irritability, sleep disturbance/fatigue, anxiety/depression, real-world functioning) was mixed and context-dependent. In samples exposed to higher psychosocial stress or financial strain, functional benefits appeared attenuated and irritability, sleep disturbance and fatigue relatively more frequent. Signals suggested moderation by drug class, dose and timing (notably late-day "booster" dosing), but direct comparative evidence was limited. Overall certainty was moderate for core symptoms and low-to-moderate for stress-linked outcomes.

Stimulants remain effective for core ADHD symptoms, but sustained stress may narrow the therapeutic window. Clinical safeguards include dose timing (avoid routine evening/booster dosing), sleep protection, load management, and proactive treatment of comorbidity. Stress-stratified trials with standardised outcomes are needed.

Not preregistered; protocol prespecified.